Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Pfizer Inc. is conducting a Phase 3 clinical study titled A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION. The study aims to assess the efficacy of elranatamab monotherapy compared to lenalidomide monotherapy in patients with newly diagnosed multiple myeloma post-transplant. This research is significant as it explores potential advancements in treatment options for multiple myeloma.
The study tests two interventions: elranatamab, a bispecific antibody designed to target and destroy multiple myeloma cells, and lenalidomide, an established immunomodulatory drug. Elranatamab is administered via injection, while lenalidomide is taken orally.
This interventional study follows a randomized, parallel assignment model with no masking, focusing on treatment as its primary purpose. Participants are allocated to receive either elranatamab or lenalidomide.
The study began on March 25, 2022, with an estimated completion date in June 2025. The primary completion date is not specified, but the last update was submitted on June 24, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The outcome of this study could significantly influence Pfizer’s stock performance and investor sentiment, especially if elranatamab proves more effective than lenalidomide. This could also impact the competitive landscape in the multiple myeloma treatment market, where innovation is highly valued.
The study is ongoing, with further details available on the ClinicalTrials portal.